Posts

Moderna Inc. said its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.

Britain’s health regulator on Wednesday approved a COVID-19 booster from Pfizer Inc and partner BioNTech SE targeting the Omicron BA.4 and BA.5 sub-variants and the original coronavirus strain.

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in humans than the original shot after one month.

German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany’s BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.

Swiss drugs regulator Swissmedic said it had been informed by vaccination centers of the appearance of bubbles during the preparation of the updated vaccine from Pfizer and BioNTech targeting the original version of the coronavirus and the BA.1 Omicron variant that led to a record surge in cases last winter.

U.S. President Joe Biden set in motion a plan to counter biological threats and prepare for the next pandemic after the COVID-19 coronavirus caused more than 1 million deaths in the United States.

The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market.

Recent studies have shown that patients with weakened immune systems — which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change — may enable the development of new, slightly different versions of the virus (variants).

Pfizer Inc. and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration’s authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years.

Moderna Inc will supply 12 million doses of its COVID-19 shot adapted to target the Omicron variant of the coronavirus to Canada, the company said on Monday.